Article
The Rheumatology Journal Club will host its next Twitter chat Thursday, Dec. 10 with two sessions beginning at 4 and 10 p.m. EST.
The Rheumatology Journal Club will host its next Twitter chat Thursday, Dec. 10 with two hour-long sessions beginning at 4 p.m. and 10 p.m. EST. The Dec. 10 session will focus on three abstracts selected by Rheumatology Journal Club followers polled in Twitter.
The Rheumatology Journal Club was launched in January 2015 by Christopher E. Collins, MD, associate professor of medicine at Georgetown University Medical Center and a member of the Rheumatology Network Editorial Board. "We're a group that is interested in applying the power of Twitter to rheumatology education through Twitter," Dr. Collins writes on the Rheumatology Journal Club website.
Each journal club Twitter chat includes:
The first four journal club chats included 133 participants from 31 countries. The majority of participants were rheumatologists, but there were physicians from eight medical specialities including nephrology, gastroenterology and geriatrics.
An analysis recently conducted by the Rheumatology Journal Club showed that the mean number of total tweets during each of the journal clubs was 493 (385 unique tweets, 108 re-tweets) with an average of 197 tweets (166 unique tweets, 31 re-tweets) during each of the live one hour sessions.
In addition to Dr. Collins (@RheumPearls), the journal club includes Paul Sufka (@psufka), MD, a rheumatologist with HealthPartners Medical Group and Regions Hospital in St. Paul, Minn.; Suleman Bhana (@DrBhana), MD, a rheumatologist in the Hudson Valley area of New York; Aruni Jayatilleke (@rheumed), MD, assistant professor of medicine at Drexel University College of Medicine; and, Jonathan Hausmann (@hausmannMD), MD, a pediatric and adult rheumatology fellow at Boston Children’s Hospital and Beth Israel Deaconess Medical Center.
For more information about the Rheumatology Journal Club, visit @RheumJC on Twitter or email rheumjc@gmail.com.
Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA